Press releases

Agreement settles all stent-related disputes between the companies.

Reinforcing company's ongoing commitment to leadership in the global medical technology market.

REPRISE II data honored as Best Abstract 2013 at PCR London valves course

Represents significant milestone toward obtaining additional key regulatory approvals for the SYNERGY™ Stent System.

Unlike medications alone, bronchial thermoplasty provides benefits that last for years rather than hours

Boston Scientific will participate in the healthcare conference on September 11 in Boston. Learn how to watch the webcast or replay.

Boston Scientific will participate in the healthcare conference on September 9 in New York. Learn how to watch the webcast or replay.

First implantations in Zhejiang province and Beijing mark the launch of the COGNIS CRT-D in the Chinese market.

Products join the company's growing portfolio of next generation EP tools designed to redefine ablation technology.

Innovative bare metal stent designed to treat Peripheral Artery Disease.

Public offering consists of $600 million of 2.650% notes due October 1, 2018 and $450 million of 4.125% notes due October 1, 2023.

Company expects to receive the net offering proceeds upon closing on August 13, 2013, subject to customary closing conditions.

"As we continue to expand our portfolio, our team is inspired to deliver meaningful innovation to more patients globally," said president and CEO Mike Mahoney.

System is next-generation 3D mapping and navigation solution for use in cardiac catheter ablations and other electrophysiology (EP) procedures.

Next generation intravascular ultrasound catheter improves image quality and deliverability

First patient treated in OPTIMISE clinical trial evaluating safety, efficacy of occipital nerve stimulation using Precision™ system.

Device facilitates delivery of interventional devices in complex PCI procedures.

Boston Scientific will webcast its conference call with financial results and business highlights for Q2 ended June 30, 2013. Learn how to tune in.

Transaction to accelerate Boston Scientific expansion in growing electrophysiology market

Cardiac pacing device also features technology to help identify patients with severe sleep apnea.

New family of pacemakers monitor respiration, adjust pacing accordingly, and support insight into the patient’s overall heart failure status.

Outcomes follow recent NICE guidance supporting safety and effectiveness of subcutaneous implantable defibrillators.

VANTAGE study interim data presented at International Congress of Parkinson's Disease and Movement Disorders in Sydney.

Boston Scientific Corporation (NYSE: BSX) announces the first implantation of its Vercise™ DBS System as part of the INTREPID clinical trial. ...

Company continues to demonstrate its commitment to women's health with a research and education grant of more than $1 million for the SUPeR clinical trial.